Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

[1]  Jianmin Wu,et al.  Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate-Resistant Prostate Cancer , 2013, Molecular Cancer Therapeutics.

[2]  F. Saad,et al.  Overview of the latest treatments for castration-resistant prostate cancer , 2013, Nature Reviews Urology.

[3]  K. Pienta,et al.  Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia , 2013, PloS one.

[4]  M. Stockler,et al.  The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC). , 2013 .

[5]  J Waxman,et al.  Circulating microRNAs as potential new biomarkers for prostate cancer , 2013, British Journal of Cancer.

[6]  P. Kantoff,et al.  Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer , 2013, The Prostate.

[7]  H. Klocker,et al.  Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.

[8]  David J. Galas,et al.  Comparing the MicroRNA Spectrum between Serum and Plasma , 2012, PloS one.

[9]  Rui Wang,et al.  MicroRNA‐200b reverses chemoresistance of docetaxel‐resistant human lung adenocarcinoma cells by targeting E2F3 , 2012, Cancer.

[10]  R. Qi,et al.  Identification of endogenous normalizers for serum MicroRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer , 2012, Hepatology.

[11]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[12]  F. Hamdy,et al.  Changes in circulating microRNA levels associated with prostate cancer , 2012, British Journal of Cancer.

[13]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[14]  L. Fink,et al.  Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. , 2011, Clinical genitourinary cancer.

[15]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[16]  R. Sutherland,et al.  Pathways of chemotherapy resistance in castration-resistant prostate cancer. , 2011, Endocrine-related cancer.

[17]  I. Pogribny,et al.  MicroRNA-mediated drug resistance in breast cancer , 2011, Clinical Epigenetics.

[18]  Jiannis Ragoussis,et al.  Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization , 2011, Nature Medicine.

[19]  X. Yao,et al.  Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy , 2011, The Prostate.

[20]  Holger Sültmann,et al.  Circulating miRNAs are correlated with tumor progression in prostate cancer , 2011, International journal of cancer.

[21]  M. Pfaffl,et al.  Normalization strategies for microRNA profiling experiments: a ‘normal’ way to a hidden layer of complexity? , 2010, Biotechnology Letters.

[22]  Stefanie Dimmeler,et al.  The microRNA-17~92 cluster: Still a miRacle? , 2009, Cell cycle.

[23]  M. Stockler,et al.  Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. , 2009, Cancer research.

[24]  E. Wentzel,et al.  miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. , 2009, Cancer research.

[25]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[26]  Giovanni Vanni Frajese,et al.  The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice , 2008, PloS one.

[27]  Anna M. Krichevsky,et al.  miR-21: a small multi-faceted RNA , 2008, Journal of cellular and molecular medicine.

[28]  Cameron P Bracken,et al.  MicroRNAs as regulators of epithelial-mesenchymal transition , 2008, Cell cycle.

[29]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[30]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[31]  Carlo M. Croce,et al.  MicroRNAs 17-5p–20a–106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation , 2007, Nature Cell Biology.

[32]  Laura Mariani,et al.  MicroRNAs modulate the angiogenic properties of HUVECs. , 2006, Blood.

[33]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[34]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[35]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[37]  C. Croce,et al.  miR221/222 in cancer: their role in tumor progression and response to therapy. , 2012, Current molecular medicine.